Bryan Baugh

701 total citations
27 papers, 321 citations indexed

About

Bryan Baugh is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Bryan Baugh has authored 27 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 12 papers in Virology and 9 papers in Emergency Medicine. Recurrent topics in Bryan Baugh's work include HIV/AIDS drug development and treatment (20 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (12 papers). Bryan Baugh is often cited by papers focused on HIV/AIDS drug development and treatment (20 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (12 papers). Bryan Baugh collaborates with scholars based in United States, Belgium and United Kingdom. Bryan Baugh's co-authors include Kimberley Brown, Ronald D’Amico, Rodica Van Solingen‐Ristea, Bruce Coate, Thomas N. Kakuda, Pieter Verboven, Herta Crauwels, Joseph Mrus, Parul Patel and Joseph W. Polli and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Bryan Baugh

27 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan Baugh United States	10	255	128	98	74	57	27	321
Barbara Heckman United States	13	254 1.0×	113 0.9×	70 0.7×	144 1.9×	25 0.4×	20	375
Ricardo Hugo de Oliveira Brazil	11	245 1.0×	122 1.0×	101 1.0×	82 1.1×	50 0.9×	25	335
Gbolahan Ajibola United States	12	269 1.1×	171 1.3×	43 0.4×	100 1.4×	53 0.9×	37	360
Alexandra Compagnucci France	12	390 1.5×	278 2.2×	93 0.9×	77 1.0×	24 0.4×	23	420
Fredy Suter Italy	11	482 1.9×	280 2.2×	171 1.7×	113 1.5×	44 0.8×	20	540
Félix Omeñaca Teres Spain	6	193 0.8×	112 0.9×	66 0.7×	139 1.9×	25 0.4×	12	331
María Espiau Spain	9	179 0.7×	26 0.2×	48 0.5×	104 1.4×	73 1.3×	37	319
Nicolette du Plessis South Africa	9	220 0.9×	56 0.4×	33 0.3×	108 1.5×	17 0.3×	22	306
Sorakij Bhakeecheep Thailand	11	302 1.2×	210 1.6×	93 0.9×	96 1.3×	10 0.2×	19	352
Patrizio Lorenzi Switzerland	5	487 1.9×	338 2.6×	141 1.4×	96 1.3×	33 0.6×	7	510

Countries citing papers authored by Bryan Baugh

Since Specialization

Citations

This map shows the geographic impact of Bryan Baugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Baugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Baugh more than expected).

Fields of papers citing papers by Bryan Baugh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Baugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Baugh. The network helps show where Bryan Baugh may publish in the future.

Co-authorship network of co-authors of Bryan Baugh

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Baugh. A scholar is included among the top collaborators of Bryan Baugh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Baugh. Bryan Baugh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Darrell H. S., Clifford Kinder, Cornelius N. Van Dam, et al.. (2024). Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. JAIDS Journal of Acquired Immune Deficiency Syndromes. 98(4). 401–409. 4 indexed citations

Polli, Joseph W., Parul Patel, Richard Grove, et al.. (2023). Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. The Journal of Infectious Diseases. 230(1). e34–e42. 10 indexed citations

Oka, Shinichi, Takuma Shirasaka, Jun Yong Choi, et al.. (2023). Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96. HIV Medicine. 25(3). 381–390. 1 indexed citations

Geurtsen, Jeroen, Bryan Baugh, Antoine C. El Khoury, et al.. (2023). Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States. BMC Infectious Diseases. 23(1). 550–550. 8 indexed citations

McKellar, Mehri S., Christopher Bettacchi, Jonathan B. Angel, et al.. (2023). 1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF. Open Forum Infectious Diseases. 10(Supplement_2). 3 indexed citations

Geurtsen, Jeroen, et al.. (2022). EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US. Value in Health. 25(7). S364–S364. 1 indexed citations

Patel, Parul, Susan L. Ford, Mark Baker, et al.. (2022). Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials. HIV Medicine. 24(5). 568–579. 32 indexed citations

Baugh, Bryan, et al.. (2022). Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD. Journal of the International Association of Providers of AIDS Care (JIAPAC). 21. 2146006474–2146006474. 1 indexed citations

Lathouwers, Erkki, et al.. (2020). Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials. Journal of Medical Virology. 93(6). 3985–3990. 2 indexed citations

10.

Huhn, Gregory, Aimee Wilkin, Cristina Mussini, et al.. (2020). Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. SHILAP Revista de lepidopterología. 21(6). 151–167. 8 indexed citations

11.

Crauwels, Herta, et al.. (2018). Bioequivalence of the Once‐Daily Single‐Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability. Clinical Pharmacology in Drug Development. 8(4). 480–491. 7 indexed citations

12.

Overton, Edgar T., Pablo Tebas, Bruce Coate, et al.. (2016). Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clinical Trials. 17(2). 72–77. 13 indexed citations

13.

Kakuda, Thomas N., Barbara M. Ryan, C. Zorrilla, et al.. (2016). Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women. HIV Medicine. 17(9). 643–652. 18 indexed citations

14.

Ramgopal, Moti, Olayemi Osiyemi, Carmen Zorrilla, et al.. (2016). Pharmacokinetics of Total and Unbound Etravirine in HIV-1–Infected Pregnant Women. JAIDS Journal of Acquired Immune Deficiency Syndromes. 73(3). 268–274. 11 indexed citations

15.

Lathouwers, Erkki, Soumi Gupta, Mojgan Haddad, et al.. (2015). Trends in Darunavir Resistance-Associated Mutations and Phenotypic Resistance in Commercially Tested United States Clinical Samples Between 2006 and 2012. AIDS Research and Human Retroviruses. 31(6). 628–635. 7 indexed citations

16.

Ofotokun, Ighovwerha, Raphael J. Landovitz, Heather J. Ribaudo, et al.. (2015). Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clinical Infectious Diseases. 60(12). 1842–1851. 58 indexed citations

17.

Wong, Eric, et al.. (2013). HIV testing practices among black primary care physicians in the United States. BMC Public Health. 13(1). 96–96. 24 indexed citations

18.

Wright, Rodney, Bryan Baugh, Kimberley Brown, et al.. (2013). Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Medicine. 15(1). 50–56. 41 indexed citations

19.

Zorrilla, C., Rodney Wright, Olayemi Osiyemi, et al.. (2012). Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV‐1‐infected pregnant women. Journal of the International AIDS Society. 15(S4). 1–2. 3 indexed citations

20.

Gupta, Samir K., et al.. (2010). Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir. Journal of the International AIDS Society. 13(S4). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact